PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
49 hedge funds and large institutions have $14M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 13 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
13% less funds holding
Funds holding: 56 → 49 (-7)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
64% less capital invested
Capital invested by funds: $38.9M → $14M (-$24.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$718K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$278K |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$154K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$141K |
| 5 |
Jane Street
New York
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.76M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.21M |
| 3 |
TCM
Towercrest Capital Management
Newtown,
Pennsylvania
|
-$1.39M |
| 4 |
VPW
Vericrest Private Wealth
Newtown,
Pennsylvania
|
-$1.39M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$322K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| – | -$30.3K | -31,698 | -99% |
|
|
SSA
52
Schonfeld Strategic Advisors
New York
| – | -$34K | -25,500 | Closed |
|
|
CSS
53
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$27K | -20,143 | Closed |
|
|
EMG
54
ETF Managers Group
Summit,
New Jersey
| – | -$21K | -14,587 | Closed |
|
|
SWM
55
Spire Wealth Management
Mclean,
Virginia
| – | -$11K | -8,000 | Closed |
|
|
CWM
56
Curi Wealth Management
Raleigh,
North Carolina
| – | -$3.11K | -3,247 | -80% |
|
|
CAGAS
57
Capital Advisory Group Advisory Services
Bloomington,
Minnesota
| – | -$4K | -2,800 | Closed |
|
58
JP Morgan Chase
New York
| – | -$1.92K | -2,000 | -99% |
|
59
Simplex Trading
Chicago,
Illinois
| – | -$888 | -927 | Closed |
|
60
Bank of America
Charlotte,
North Carolina
| – | +$184 | +192 | +19,200% |
|
PHAS Hedge Fund Activity: Q2 2022 in Review
49 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q2 2022, worth a combined $14M — down 64% from $38.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PHAS and 6 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was CHI Advisors, opening a new position worth an estimated $718K. The largest seller was RA Capital Management, exiting entirely with an estimated $3.76M sold.
- 49 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q2 2022, down from 56 in Q1 2022.
- Funds reported $14M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 64% quarter-over-quarter.
- 6 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 13 closed out, a net change of -7 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was CHI Advisors, an estimated $718K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was RA Capital Management, an estimated $3.76M sold.
Based on aggregated 13F filings for Q2 2022.